Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4465-4478
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465
Figure 2
Figure 2 Progression-free survival of hepatocellular carcinoma patients treated with lenvatinib. The median progression-free survival was estimated to be 168 d (95%CI: 130–205 d).